Cancer is associated with immune dysfunction characterized by the presence of proinflammatory and immunosuppressive cells and factors that contribute to tumor growth and progression. Here we show that mammary tumor growth is associated with defects in hematopoiesis leading to myeloproliferative-like disease (leukemoid reaction), anemia and disruption of the bone marrow stem/progenitor compartment. The defects we characterized included impaired erythropoiesis, leukocytosis, loss of early progenitor cells in the bone marrow and splenic extramedullary hematopoiesis. We established an in vitro model to dissect interactions between mammary cancers and the hematopoietic system. Investigations in this model revealed that G-CSF produced by mammary tumors can synergize with FLT3L and GM-CSF to expand myeloid progenitors and their progeny in culture. Mammary tumor growth was associated with histone methylation changes within lineagenegative c-Kit-positive (LK) hematopoietic cells within the bone marrow of tumor-bearing mice.
Introduction
The link between cancer and inflammation has been recognized for almost 150 years (1) .
However, the complexity of the interactions between tumors and the immune system is only beginning to be appreciated. Solid tumor development is often associated with cytokine and metabolite upregulation, and immunosuppressive cell expansion (including myeloid-derived suppressor cells (MDSCs), T regulatory cells, tumor-associated macrophages (TAMs), and tumor-associated dendritic cells (tDCs)). These cells facilitate tumor growth, metastasis and immunological escape (2) . Cancer is also frequently associated with perturbations in hematopoiesis manifested as disturbed myelopoiesis, leukocytosis (leukemoid reaction), cytopenia and/or anemia, which may predict adverse patient outcome (3, 4) . Since the nature of anti-tumor immune responses may hold better prognostic value than standard scoring regimes, a better understanding of tumor-induced changes to the immune response and hematopoietic system may lead to improved cancer diagnosis and treatment (5) . Indeed, recent studies show that manipulation of tumor-induced stromal cells can impair tumour growth and elicit anti-tumor immunity (6) .
Development of blood cell lineages is controlled by sequential differentiation of progressively restricted progenitor populations derived from hematopoietic stem cells (HSCs). Gene expression patterns governing blood cell production and lineage commitment are regulated by transcription factors and epigenetic control of chromosomal organization involving histone modifications and DNA methylation (7) . Epigenetic changes are linked to control of cell fate, stem/progenitor cell function and tumorigenesis. In leukemia and myeloid neoplasia, epigenetic dysregulation induced by mutations in DNA-or histone-modifying genes is a significant step in disease progression. Mutations in genes encoding Trithorax group (TrxG) and Polycomb group (PcG) proteins regulating histone H3 lysine-4 (H3K4) and lysine-27 (H3K27) methylation, respectively, are frequently observed in hematological 4 malignancies and myeloproliferative/dysplastic neoplasms (8, 9) . H3K4 trimethylation (H3K4me   3   ) correlates with enhanced gene expression, while H3K27 trimethylation (H3K27me 3 ) is generally linked to suppression of gene expression. EZH2, the H3K27 methyltransferase component of Polycomb repressive complex2 (PRC2), plays complex roles in leukocyte neoplasms with both loss-and gain-offunction mutations in Ezh2 associated with disease. EZH2 catalyzes progressive H3K27 methylation, resulting in suppression of genes including Hoxa9 (10, 11) , with recent work revealing a role for PRC2 in HSC physiology (12, 13) . Hoxa genes regulate steady state hematopoiesis governing stem/progenitor cell function. As blood cells differentiate, expression of Hoxa genes decreases, a process involving changes in H3K27 methylation catalyzed by enzymes like JMJD3 (14, 15) . Hoxa gene family upregulation, particularly Hoxa7 and Hoxa9, promote hematopoietic stem/progenitor cell (HSPC) expansion and contribute to leukemogenic transformation (16, 17) .
Here, we assessed the HSPC compartments in tumor-bearing mice and found that mammary tumors (MTs) induced greater changes in hematopoiesis than previously appreciated. All MTs examined affected primitive HSPC compartments leading to myeloproliferative-like disease (leukocytosis) and anemia. MT growth was associated with diminished Ezh2 expression, reduced We established an in vitro model to decipher the tumour-secreted and endogenous factors that might contribute to dysregulation of hematopoiesis, and found that the hematopoietic regulatory cytokines FLT3L and GM-CSF synergized with MT-produced G-CSF to enhance HSPC production.
Additionally, MT-secreted factors led to global and gene-specific changes in histone methylation patterns associated with enhanced Hoxa9 gene expression. Taken together, our data suggests that MT- secreted factors such as G-CSF lead to epigenetic changes and altered expression of key hematopoietic regulatory genes, ultimately resulting in leukocytosis, anemia and HSPC defects.
Materials and methods

Mice. MMTV-neu
OTI/OTII mice were previously described (18, 19 (18, 19) . NOP cells were maintained in RPMI-1640 (Invitrogen), 10% heat-inactivated (HI)-FBS, 100U/mL penicillin-G, 100μg/mL streptomycin, 2mM Menin inhibitor treatment of BM cultures. BM was treated with menin inhibitors, MI-2/MI-3, on d0 of culture and analyzed on d3 for CFCs. Alternatively, inhibitors were added on d0 and cells were analyzed on d8 by flow/qPCR. For Hoxa9 qPCR, cells were treated for 24hrs with MI-2/MI-3.
Statistical analysis. Statistical comparisons were performed using unpaired t-test. Error bars and ± symbols represent SEM. *,P<0.05, **,P<0.01, ***,P<0.001, ****,P<0.0001.
Reagents, antibodies, competitive-reconstitution, CFU-S 12 assay, chromatin immunoprecipitation (ChIP), qPCR, methylcellulose assay and Western blot. See supplemental materials and methods.
Results
Mammary tumors induce widespread changes in hematopoiesis.
Cancer is frequently associated with immune system perturbations, with the tumor microenvironment known to reprogram myeloid cells into MDSCs, TAMs and/or tDCs. We employed previously described MMTV-neu
OTI/OTII
MT lines (MT1-4) that are syngeneic to C57BL/6-neu OTI/OTII transgenic mice (18, 19) . Tumor development was associated with a 3-7 fold increase in white blood cells (WBC) due to a 7-10 fold increase in granulocytes. We also observed decreased hematocrit, red blood cells (RBC), hemoglobin (HGB) and platelets (PLT), in MT-bearing mice (Table 1) . Changes in monocyte and granulocyte frequency/numbers were confirmed by flow cytometry of blood, BM and spleen ( Figure S1A ). We observed increased splenic cellularity, monocytes (CD115 To further investigate the impact of MT growth on HSPCs we assessed progenitor numbers using the methylcellulose colony-forming and CFU-S 12 assays, and stem cell functionality by competitive repopulation in radiation chimeric mice. Methylcellulose assays revealed increased splenic myeloid progenitors in MT-bearing mice, correlating with increased LKs (Figures 3A,2C ). By contrast, BM CFU-G/M/GM numbers were similar in control and MT-bearing mice ( Figure 3A ). The CFU-S 12 assay identifies primitive multi-potent progenitor populations (21) . Surprisingly, BM from MT-bearing mice exhibited a 5-10 fold loss in primitive progenitor activity ( Figure 3B Mammary/breast cancers can produce and enhance stromal cell production of cytokines including M-CSF, IL-6, VEGF, and G-CSF, which may contribute to tumor growth/spread (23, 24 We tested whether mammary cancer-produced factors could synergize with FLT3L in cultured BM by assessing cytokine-induced changes in cellularity and LSK/LK content. Alone, no tested factors enhanced LSK numbers, however, IL-6 and G-CSF synergized with FLT3L, increasing total cellularity and LSK/LKs comparable to MT-CM ( Figure 4A ,C,data not shown). Other factors tested did not increase LSKs in combination with FLT3L, although some increased cell numbers ( Figure 4C ). We used a cytokine array to identify MT-1-secreted factors and found abundant G-CSF (of 40 cytokines/chemokines tested), and low IL-6 ( Figure S4B ). We confirmed that only MT cell lines MT1-4 and 4T1 secreted G-CSF ( Figure S4C ). Additionally, G-CSF was elevated in the serum of MT-1 bearing mice ( Figure S4C To determine whether histone methylation changes were required for MT-CM bioactivity, we employed recently described menin inhibitors MI-2 and MI-3, which attenuate H3K4me 
tumor-promoting TAMs, MDSCs and/or tDCs, and recent reports have revealed how significant these tumor-induced perturbations in the immune system are and have highlighted the need to better understand these perturbations to improve strategies to initiate or re-invigorate anti-tumor immune responses (32). In the case of breast cancer, the immune status of the tumor may predict treatment outcome (33). As different cancers affect the immune system uniquely, understanding these interactions will help predict patient responses to therapy and to advance immunotherapy strategies.
Here we show that mammary cancer affects the primitive HSPC compartments of the hematopoietic system leading to a myeloproliferative-like disease characterized by neutrophilia, anemia and HSPC defects. Importantly, tumor-induced changes were observed using five different MT- Tumors can express cytokines and factors important for tumor growth, survival or spread, e.g.
the 4T1 MT line expresses GM-CSF, G-CSF and M-CSF associated with a leukemoid reaction (39).
We showed that G-CSF was an abundant factor secreted by MTs, and used loss-and gain-of-function experiments to confirm that G-CSF present in MT-CM synergized with FLT3L and GM-CSF to used loss-and gain-of-function experiments to show that tumour-secreted G-CSF increases tumour growth, splenomegaly and MDSC production in mice, although the underlying mechanisms leading to these changes were not explored (40) . G-CSF can also impair erythropoiesis and synergize with FLT3L to mobilize stem cells (41) .
G-CSF is produced by many human tumours, including pancreatic, cervical, bladder and breast (42, 43) . G-CSF is elevated in breast carcinomas compared to healthy breast tissue (44) . Similarly, G-CSF mRNA is elevated in breast cancer tissues compared to surrounding healthy tissues and G-CSF levels were higher in the serum of breast cancer patients compared to healthy controls (45) . The association between increased G-CSF and breast cancer clinical grade and lymph node infiltration has been established, further supporting its role in tumor progression and disease severity (46, 47) . 3 /µL 0.3 ± 0.0 0.7 ± 0.1*** 0.8 ± 0.1 1.5 ± 0.2* GRA, 10 3 /µL 2.5 ± 0.3 18.3 ± 2.5**** 2.4 ± 0.2 23.9 ± 6.1* RAG1 -/-: Control n=13, MT-1 n=12; B6: Control n=4, MT-1 n=4. Blood was obtained from cardiac puncture and analyzed on a scil Vet abc hematology analyzer, scil animal care company, Gurnee, IL. *, P < .05; **, P < .01; **, P < .001; ****, P < .0001. WBC indicates white blood cell; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; PLT, platelet; LYM, lymphocyte; MON, monocyte; GRA, granulocyte. 
